28
total announcements
SYNGENE.NS · 15 min delayed
Syngene International Limited
Syngene International Limited has informed the Exchange about the schedule of a meeting with analysts/institutional investors, to be held on August 31, 2026, and September 1, 2026, in Hong Kong. The company will not disclose any unpublished price sensitive information during the meeting.
Syngene International Limited
Syngene International Limited has informed the Exchange about Acquisition of AMPIN C&I Power Twelve Private Limited for the purpose of acquisition of renewable power. The acquisition aligns with the Company’s renewable energy objectives, supporting the procurement of green energy and advancing its decarbonization goals.
Syngene International Limited
Syngene International Limited has informed the Exchange about the schedule of a meeting with analysts/institutional investors, to be held virtually on August 28, 2026. The meeting timings are 12:00 PM IST. The company will not disclose any unpublished price sensitive information during the meeting.
Syngene International Limited
Syngene International Limited has informed the Exchange about the schedule of a meeting with analysts/institutional investors, to be held on August 13 and 14, 2026, in Mumbai. The meeting is organized by Emkay Global, and the company will not disclose any unpublished price sensitive information (UPSI) during the meeting.
Syngene International Limited
Syngene International Limited has informed the Exchange about the transcript of the Q1 FY2027 Earnings Conference call held on July 30, 2026, which is uploaded on the Company’s website.
Syngene International Limited
Syngene International Limited has submitted the Exchange a copy Scrutinizer's report of Annual General Meeting held on July 29, 2026. Further, the company has informed the Exchange regarding voting results.
Syngene International Limited
Syngene International Limited has informed the Exchange about the link of the recording of its Q1 FY27 post-earnings call, which was conducted on July 30, 2026, and is available on the company's website.
Syngene International Limited
Syngene International Limited has informed the Exchange about the publication of their financial results for the quarter ended June 30, 2026, in the Financial Express (All India Edition) and Vijayavani (Bengaluru Edition) newspapers.
Syngene International Limited
Syngene International Limited has released an investor presentation for the quarter ended June 30, 2026, highlighting its Q1 FY27 performance, including revenue from operations of Rs 736 Cr (-16% Y-o-Y), operating EBITDA margin of 12%, and PAT of Rs 1 Cr. The company has also signed a Memorandum of Understanding with BRIC-Translational Health Science and Technology Institute (THSTI) for a joint operational partnership for early and late-phase clinical development, translational research, and bioanalytical sciences.
Syngene International Limited
Syngene International Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 29, 2026. The meeting was held through video conferencing and 117 members were present. The company adopted audited financial statements and declared a final dividend of Rs. 1.25 per equity share.
Syngene International Limited
Syngene International Limited has informed the Exchange about the resignation of a Director/KMP/SMP.
Syngene International Limited
Syngene International Limited has informed the Exchange regarding Resignation of Mr Kush Parmar as Independent Director of the company w.e.f. July 29, 2026.
Syngene International Limited
Syngene International Limited has announced its Q1 FY27 results, with revenue from operations at Rs. 736 Cr and operating EBITDA at Rs. 91 Cr, showing a decline of 16% and 56% respectively compared to Q1 FY26.
Syngene International Limited
Syngene International Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, with a profit before tax of Rs. 192 million and a profit for the period of Rs. 90 million. The company's revenue from operations was Rs. 7,360 million, and its expenses were Rs. 7,670 million. The results also include a statement of unaudited consolidated financial results.
Syngene International Limited
Syngene International Limited has informed the Exchange about a conference call with analysts and investors to discuss Q1 FY 2026-27 financial results on July 30, 2026.
Syngene International Limited
Syngene International Limited has informed the Exchange about change in Management due to General Counsel Surender Sharma leaving the Company by mutual consent to pursue other career opportunities.
Syngene International Limited
Syngene International Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities during the quarter ended June 30, 2026.
Syngene International Limited
Syngene International Limited has informed the Exchange about the resignation of its Statutory Auditor.
Syngene International Limited
Syngene International Limited has informed the Exchange regarding Resignation of M/s B S R & Co. LLP, Statutory Auditor of material subsidiary Syngene Scientific Solutions Limited, effective July 07, 2026.
Syngene International Limited
Syngene International Limited has informed the Exchange about the receipt of an order dated May 14, 2026, giving effect to the order passed by the National Faceless Appeal Centre (NFAC) for Assessment Year (AY) 2014-15. The order partly allowed the appeal and granted a refund of Rs. 8,62,14,600/- (including interest). The Company believes there may not be material impact on its financials, operations, or activities.